IL-6、IL-6R及MCL-1在多发性骨髓瘤患者中的表达及临床意义

目的:分析白细胞介素-6(IL-6)及其受体(IL-6R)、髓样细胞白血病蛋白-1(MCL-1)在多发性骨髓瘤(MM)患者中表达水平的变化及其临床意义。方法:选取2014年1月-2019年1月期间唐山市工人医院和唐山市人民医院收治的多发性骨髓瘤患者98例,根据DS分期将患者分为3组:Ⅰ期27例,Ⅱ期34例,Ⅲ期37例。比较不同DS分期患者的IL-6、IL-6R及MCL-1的表达水平,并分析患者预后的相关因素。结果:3组患者IL-6及MCL-1表达水平随着DS分期升高而升高,组间差异具有统计学意义(P<0.05),3组患者IL-6R表达水平无明显差异(P>0.05)。比较不同IL-6及MCL-1表达水平患者的预后,结果显示,IL-6≥80 pg/ml的患者(41例)的中位生存时间为33.0个月,<80 pg/ml的患者(57例)的中位生存时间为33.5个月,差异无统计学意义(P>0.05)。MCL-1≥200 pg/ml的患者(45例)的中位生存时间为30.5个月,<200 pg/ml患者(53例)的中位生存时间为37.0个月,差异具有统计学意义(P<0.05)。性别、年龄、β2-MG及Hb与患者预后无明显相关性(P>0.05),而DS分期、IL-6及MCL-1与预后相关(r=0.857,r=0.764,r=0.802)。结论:多发性骨髓瘤患者的IL-6及MCL-1水平与患者的DS分期及预后相关。

Expression and Clinical Sgnificance of IL-6,IL-6R and MCL-1 in Patients with Multiple Myeloma

Objective:To study the expression level and clinical significance of serum interleukin-6(IL-6),its receptor(IL-6 R)and myeloid cell leukemin-1(MCL-1)in patients with multiple myeloma(MM).Methods:Ninetyeight cases of MM treated in our hospital from January 2014 to January 2019 were selected,and the patients were divided into three groups according to their DS stage:stageⅠ(27 cases),stageⅡ(34 cases)and stageⅢ(37 cases).The expression levels of IL-6,IL-6 R and MCL-1 in patients at different DS stages were compared,and the prognostic-related factors were analyzed.Results:The expression levels of IL-6 and MCL-1 in patients rised with DS stages,and the difference showed statistical significance(P<0.05),but the level of IL-6 R in three groups showed no significant difference(P>0.05).The prognosis of patients with different levels of IL-6 and MCL-1 was compared and the results were as follows,the median survival time of 41 patients with IL-6≥80 pg/ml was 33.0 months,and that of 57 patients with IL-6<80 pg/ml was 33.5 months,which showed no significant difference(P>0.05).The median survival time of 45 patients with MCL-1≥200 pg/ml was 30.5 months,and that of 53 patients with MCL-1<200 pg/ml was 37.0 months,and their difference was statistically significant(P<0.05).Sex,age,β2-MG and Hb not significantly correlated with prognosis of patients(P>0.05),however,DS stage,IL-6 and MCL-1 correlated with prognosis of patients(r=2.261,r=1.754,r=1.905).Conclusion:The levels of IL-6 and MCL-1 in patients with multiple myeloma correlate with the DS stage and prognosis of patients.